Company profile · Biotech & medical
Senhwa Biosciences
生華生物科技股份有限公司 · 6492
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Senhwa Biosciences develops novel anticancer drugs with novel mechanisms to provide effective treating methods for cancers.[1]
The company's main development projects for novel drugs are novel small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) and inhibitor of protein kinase CK2 Silmitasertib (CX4945).[1]
Pidnarulex applies to the treatment of breast cancer and other homologous repair deficiency or tumors from BRCA1/2 gene mutation.[1]
Silmitasertib applies to the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma.[1]
The company is based in New Taipei City, Taiwan.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$0m | +0.0% | +0.0% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$4m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | Senhwa Biosciences, Inc. |
|---|---|
| Chinese name | 生華生物科技股份有限公司 |
| Stock code | 6492 (TPEx) |
| Industry | Biotech & medical |
| Founded | 16 Nov 2012 |
| Listed | 24 Apr 2017 |
| Paid-in capital | NT$1.1bn |
| Chairman | 胡定吾 |
| President | 黃品諺 |
| Headquarters | 10F., No. 225, Sec. 3, Peihsin Rd., Hsintien Dist., New Taipei City, Taiwan |
| Website | http://www.senhwabio.com |
| Official business description | 抗癌新藥及特殊原料藥研發 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
- MOPS 公司基本資料 生華生物科技股份有限公司 · mops · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list